DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Piclamilast
Piclamilast
Download Product Insert (PDF)
[3H]-Piclamilast and [3H]-Rolipram
Chapter Introduction
Stems for Nonproprietary Drug Names
Phosphodiesterase (PDE)
Inhibition of Phosphodiesterase 4 Modulates Cytokine Induction From
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Suplementum 12/1 MAKETA 7/1 2/23/12 12:12 PM Stránka 16
New Therapeutic Options in the Management of COPD – Focus on Roflumilast
Downloaded from Survive Nursing | Survivenursing.Com V20110426
Selective Phosphodiesterase 4 Inhibitors
1 Elevated Intracellular Camp Concentration Mediates Growth
Stembook 2018.Pdf
Phosphodiesterase 4 Inhibitors for the Treatment of Inflammation Associated with Respiratory Disease
Inflammatory Effects of the Novel Inhaled
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
Insight Into the Molecular Interaction of Anti Malarial Compounds As Potential Chorismate Synthase Inhibitors
Phosphodiesterase 4 Inhibition Attenuates Pulmonary Inflammation in Neonatal Lung Injury
Top View
Customs Tariff - Schedule
Pathobiological Mechanisms and Treatment of Electrophysiological Dysfunction Following Primary Blast-Induced Traumatic Brain Injury
Elevated Intracellular Camp Concentration Mediates Growth Suppression in Glioma Cells
Anti‑Inflammatory Effect of Ciclamilast in an Allergic Model Involving the Expression of PDE4B
2010-Poster Tms
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
PR 6 2010.Vp:Corelventura
(12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
WO 2018/005695 Al O
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
FMO3 Inhibitors for Treating Pain
Phosphodiesterase 4 Inhibition Reduces Lung Fibrosis Following Targeted Type II Alveolar Epithelial Cell Injury
WO 2018/055211 Al 29 March 2018 (29.03.2018) W !P O PCT
Pharmaabkommen A1 E
Roles of Roflumilast, a Selective Phosphodiesterase 4 Inhibitor, in Airway Diseases
Customs Tariff - Schedule Xxi - 1
Literature Search Strategy for Treatment of Stable
(12) Patent Application Publication (10) Pub. No.: US 2003/0144300 A1 Magee Et Al
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pyrrolotriazinone Derivatives As PI3K Inhibitors
Are Vasopressors Useful in Toxin-Induced Cardiogenic Shock?
Elevated Cyclic AMP and PDE4 Inhibition Induce Chemokine Expression in Human Monocyte-Derived Macrophages
(12) Patent Application Publication (10) Pub. No.: US 2003/0134861A1 Doherty, JR
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Phosphodiesterase 4 Inhibition Reduces Lung Fibrosis Following
Harmonized Tariff Schedule of the United States (2006) (Rev
Evalua on of Human PDE4 Inhibitors Cilomilast and Piclamilast As Lead
WO 2017/033032 Al 2 March 2017 (02.03.2017) P O P C T
Ep 2741739 B1
022522Orig1s000
The Role of PDE4 in Pulmonary Inflammation and Goblet Cell
(12) Patent Application Publication (10) Pub. No.: US 2016/0235807 A1 SHALUBHA (43) Pub
Selective Inhibition of Purified Human Phosphodiesterase 4A Expressed in Yeast Cell GL62 by Ciclamilast, Piclamilast, and Rolipram1
(12) Patent Application Publication (10) Pub. No.: US 2010/0022563 A1 Henkin (43) Pub